Moreover, in a SSc mouse model, a significant reduction of lung inflammation and pulmonary fibrosis was observed in the IL-22-deficient mice after they received high doses of bleomycin [92], indicating a pathogenic aspect of IL-22 in SSc. This evidence concerns the gene IL22 and systemic sclerosis.